Results · Apr-Jun 2026
Medicamen Biotech Q1 FY27 results
Sales grew 11% to ₹47.9 crore from ₹43 crore in Apr-Jun 2025.
Operating profit fell 6% to ₹4.3 crore, an operating margin of 9.0% (down 1.7 points from a year ago).
Net profit grew 15% to ₹1.8 crore from ₹1.6 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −21%, net profit −58%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 47.9 | 43.0 | +11% |
| Operating profit (EBITDA) | 4.3 | 4.6 | −6% |
| Operating margin | 9.0% | 10.7% | −1.7 pts |
| Net profit | 1.8 | 1.6 | +15% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.